Latest Avastin Stories
Genentech, Inc. (NYSE:DNA) today announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin(R) (bevacizumab) as a therapy for people with previously treated glioblastoma.
Genentech, a biotechnology company, has announced that it has been informed by the National Surgical Adjuvant Breast and Bowel Project that an ongoing Phase III study of Avastin plus chemotherapy in patients with early-stage colon cancer will continue as planned.
Genentech, Inc. (NYSE:DNA) today announced that it has been informed by the National Surgical Adjuvant Breast and Bowel Project (NSABP) that an ongoing Phase III study (NSABP C-08) of Avastin(R) (bevacizumab) plus chemotherapy in patients with early-stage colon cancer will continue as planned.
WALTHAM, Mass., Oct.
By ; wire Shares of South San Francisco-based Genentech dropped nearly 8 percent after the company announced with OSI Pharmaceuticals that a combination of two cancer drugs, Avastin with Tarceva, missed its primary goal in a clinical trial, failing to improve survival for patients with late-stage lung cancer.
Blockbuster cancer drug Avastin has suffered a setback, failing to improve overall survival when added to Tarceva in a Phase III trial for second-line advanced non-small cell lung cancer.
Genentech and OSI Pharmaceuticals have announced that a randomized Phase III study evaluating Avastin in combination with Tarceva in patients with advanced non-small cell lung cancer whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo.
Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc.
By DOMINIC JEFF Herald Reporter A plymouth woman fighting to get a life-extending drug on the NHS has launched a petition for people to support her appeal. Stephanie Chouette, aged 34, has breast cancer which has spread to her vertebrae and liver, and has only a few months to live.
SCOTTSDALE, Ariz., Sept. 29 /PRNewswire/ -- NeoVista, Inc.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.